101
|
MacDonald D, Martin M, Nguyen C. Malignant lesions in the anterior maxilla. Clin Radiol 2020; 75:497-506. [DOI: 10.1016/j.crad.2019.09.133] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2019] [Accepted: 09/23/2019] [Indexed: 12/16/2022]
|
102
|
Vignot S, Blaise T, Martin M. Nouvelles modalités de prescription des ATU nominatives : un dispositif à la mesure des besoins en infectiologie. Med Mal Infect 2020; 50:386-387. [DOI: 10.1016/j.medmal.2019.10.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2019] [Revised: 08/06/2019] [Accepted: 10/18/2019] [Indexed: 10/25/2022]
|
103
|
Maitre I, Roger A, Lesourd B, Sulmont-Rossé C, Corbière T, Martin M, Levasseur M, Van Wymelbeke V. À domicile : comment accompagner les aidants pour mieux nourrir les aidés ? NUTR CLIN METAB 2020. [DOI: 10.1016/j.nupar.2020.02.359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
104
|
Tintó-Moliner A, Martin M. Quantitative weight of evidence method for combining predictions of quantitative structure-activity relationship models. SAR AND QSAR IN ENVIRONMENTAL RESEARCH 2020; 31:261-279. [PMID: 32065534 DOI: 10.1080/1062936x.2020.1725116] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/25/2019] [Accepted: 01/30/2020] [Indexed: 06/10/2023]
Abstract
A method for combining statistical-based QSAR predictions of two or more binary classification models is presented. It was assumed that all models were independent. This facilitated the combination of positive and negative predictions using a quantitative weight of evidence (qWoE) procedure based on Bayesian statistics and the additivity of the logarithms of the likelihood ratios. Previous studies combined more than one prediction but used arbitrary strengths for positive and negative predictions. In our approach, the combined models were validated by determining the sensitivity and specificity values, which are performance metrics that are a point of departure for obtaining values that measure the weight of evidence of positive and negative predictions. The developed method was experimentally applied in the prediction of Ames mutagenicity. The method achieved a similar accuracy to that of the experimental Ames test for this endpoint when the overall prediction was determined using a combination of the individual predictions of more than one model. Calculating the qWoE value would reduce the requirement for expert knowledge and decrease the subjectivity of the prediction. This method could be applied to other endpoints such as developmental toxicity and skin sensitisation with binary classification models.
Collapse
|
105
|
Phad GE, Pushparaj P, Tran K, Dubrovskaya V, Àdori M, Martinez-Murillo P, Vázquez Bernat N, Singh S, Dionne G, O’Dell S, Bhullar K, Narang S, Sorini C, Villablanca EJ, Sundling C, Murrell B, Mascola JR, Shapiro L, Pancera M, Martin M, Corcoran M, Wyatt RT, Karlsson Hedestam GB. Extensive dissemination and intraclonal maturation of HIV Env vaccine-induced B cell responses. J Exp Med 2020; 217:e20191155. [PMID: 31704807 PMCID: PMC7041718 DOI: 10.1084/jem.20191155] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Revised: 09/12/2019] [Accepted: 10/03/2019] [Indexed: 12/22/2022] Open
Abstract
Well-ordered HIV-1 envelope glycoprotein (Env) trimers are prioritized for clinical evaluation, and there is a need for an improved understanding about how elicited B cell responses evolve following immunization. To accomplish this, we prime-boosted rhesus macaques with clade C NFL trimers and identified 180 unique Ab lineages from ∼1,000 single-sorted Env-specific memory B cells. We traced all lineages in high-throughput heavy chain (HC) repertoire (Rep-seq) data generated from multiple immune compartments and time points and expressed several as monoclonal Abs (mAbs). Our results revealed broad dissemination and high levels of somatic hypermutation (SHM) of most lineages, including tier 2 virus neutralizing lineages, following boosting. SHM was highest in the Ab complementarity determining regions (CDRs) but also surprisingly high in the framework regions (FRs), especially FR3. Our results demonstrate the capacity of the immune system to affinity-mature large numbers of Env-specific B cell lineages simultaneously, supporting the use of regimens consisting of repeated boosts to improve each Ab, even those belonging to less expanded lineages.
Collapse
|
106
|
Garcia M, Juhos S, Larsson M, Olason PI, Martin M, Eisfeldt J, DiLorenzo S, Sandgren J, Díaz De Ståhl T, Ewels P, Wirta V, Nistér M, Käller M, Nystedt B. Sarek: A portable workflow for whole-genome sequencing analysis of germline and somatic variants. F1000Res 2020; 9:63. [PMID: 32269765 PMCID: PMC7111497 DOI: 10.12688/f1000research.16665.2] [Citation(s) in RCA: 64] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 07/03/2020] [Indexed: 12/13/2022] Open
Abstract
Whole-genome sequencing (WGS) is a fundamental technology for research to advance precision medicine, but the limited availability of portable and user-friendly workflows for WGS analyses poses a major challenge for many research groups and hampers scientific progress. Here we present Sarek, an open-source workflow to detect germline variants and somatic mutations based on sequencing data from WGS, whole-exome sequencing (WES), or gene panels. Sarek features (i) easy installation, (ii) robust portability across different computer environments, (iii) comprehensive documentation, (iv) transparent and easy-to-read code, and (v) extensive quality metrics reporting. Sarek is implemented in the Nextflow workflow language and supports both Docker and Singularity containers as well as Conda environments, making it ideal for easy deployment on any POSIX-compatible computers and cloud compute environments. Sarek follows the GATK best-practice recommendations for read alignment and pre-processing, and includes a wide range of software for the identification and annotation of germline and somatic single-nucleotide variants, insertion and deletion variants, structural variants, tumour sample purity, and variations in ploidy and copy number. Sarek offers easy, efficient, and reproducible WGS analyses, and can readily be used both as a production workflow at sequencing facilities and as a powerful stand-alone tool for individual research groups. The Sarek source code, documentation and installation instructions are freely available at
https://github.com/nf-core/sarek and at
https://nf-co.re/sarek/.
Collapse
|
107
|
Garcia M, Juhos S, Larsson M, Olason PI, Martin M, Eisfeldt J, DiLorenzo S, Sandgren J, Díaz De Ståhl T, Ewels P, Wirta V, Nistér M, Käller M, Nystedt B. Sarek: A portable workflow for whole-genome sequencing analysis of germline and somatic variants. F1000Res 2020; 9:63. [DOI: 10.12688/f1000research.16665.1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 01/23/2020] [Indexed: 01/08/2023] Open
Abstract
Whole-genome sequencing (WGS) is a fundamental technology for research to advance precision medicine, but the limited availability of portable and user-friendly workflows for WGS analyses poses a major challenge for many research groups and hampers scientific progress. Here we present Sarek, an open-source workflow to detect germline variants and somatic mutations based on sequencing data from WGS, whole-exome sequencing (WES), or gene panels. Sarek features (i) easy installation, (ii) robust portability across different computer environments, (iii) comprehensive documentation, (iv) transparent and easy-to-read code, and (v) extensive quality metrics reporting. Sarek is implemented in the Nextflow workflow language and supports both Docker and Singularity containers as well as Conda environments, making it ideal for easy deployment on any POSIX-compatible computers and cloud compute environments. Sarek follows the GATK best-practice recommendations for read alignment and pre-processing, and includes a wide range of software for the identification and annotation of germline and somatic single-nucleotide variants, insertion and deletion variants, structural variants, tumour sample purity, and variations in ploidy and copy number. Sarek offers easy, efficient, and reproducible WGS analyses, and can readily be used both as a production workflow at sequencing facilities and as a powerful stand-alone tool for individual research groups. The Sarek source code, documentation and installation instructions are freely available at https://github.com/nf-core/sarek and at https://nf-co.re/sarek/.
Collapse
|
108
|
Peters LJ, Martin M, Forgas L, Glass R. The Oklahoma Canine Oral Health Index. J Vet Dent 2020. [DOI: 10.1177/089875648800500307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
109
|
Martin M, Decamps P, Seguin A, Garret C, Crosby L, Zambon O, Miailhe AF, Canet E, Reignier J, Lascarrou JB. Nationwide survey on training and device utilization during tracheal intubation in French intensive care units. Ann Intensive Care 2020; 10:2. [PMID: 31900637 PMCID: PMC6942097 DOI: 10.1186/s13613-019-0621-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2019] [Accepted: 12/23/2019] [Indexed: 11/29/2022] Open
Abstract
Background Intubation is a lifesaving procedure that is often performed in intensive care unit (ICU) patients, but leads to serious adverse events in 20–40% of cases. Recent trials aimed to provide guidance about which medications, devices, and modalities maximize patient safety. Videolaryngoscopes are being offered in an increasing range of options and used in broadening indications (from difficult to unremarkable intubation). The objective of this study was to describe intubation practices and device availability in French ICUs. Materials and methods We conducted an online nationwide survey by emailing an anonymous 26-item questionnaire to physicians in French ICUs. A single questionnaire was sent to either the head or the intubation expert at each ICU. Results Of 257 ICUs, 180 (70%) returned the completed questionnaire. The results showed that 43% of intubators were not fully proficient in intubation; among them, 18.8% had no intubation training or had received only basic training (lectures and observation at the bedside). Among the participating ICUs, 94.4% had a difficult intubation trolley, 74.5% an intubation protocol, 92.2% a capnography device (used routinely to check tube position in 69.3% of ICUs having the device), 91.6% a laryngeal mask, 97.2% front-of-neck access capabilities, and 76.6% a videolaryngoscope. In case of difficult intubation, 85.6% of ICUs used a bougie (154/180) and 7.8% switched to a videolaryngoscope (14/180). Use of a videolaryngoscope was reserved for difficult intubation in 84% of ICUs (154/180). Having a videolaryngoscope was significantly associated with having an intubation protocol (P = 0.043) and using capnography (P = 0.02). Airtraq® was the most often used videolaryngoscope (39.3%), followed by McGrath®Mac (36.9%) then by Glidescope® (14.5%). Conclusion Nearly half the intubators in French ICUs are not fully proficient with OTI. Access to modern training methods such as simulation is inadequate. Most ICUs own a videolaryngoscope, but reserve it for difficult intubations.
Collapse
|
110
|
Figueroa CL, Bernabe LF, Martin M, Vidal E, Pérez de Val B, Ramis A. A Case of Canine Miliary Tuberculosis Caused by Mycobacterium tuberculosis. J Comp Pathol 2020. [DOI: 10.1016/j.jcpa.2019.10.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
111
|
Avnery O, Martin M, Bura-Riviere A, Barillari G, Mazzolai L, Mahé I, Marchena PJ, Verhamme P, Monreal M, Ellis MH, Aibar MA, Aibar J, Amado C, Arcelus JI, Ballaz A, Barba R, Barrón M, Barrón‐Andrés B, Bascuñana J, ina A, Camon AM, Cañas I, Carrasco C, Castro J, Ancos C, Toro J, Demelo P, Díaz‐Peromingo JA, Falgá C, Farfán AI, Fernández‐Capitán C, Fernández‐Criado MC, Fernández‐Núñez S, Fidalgo MA, Font C, Font L, Freire M, Gallego M, García MA, García‐Bragado F, García‐Morillo M, García‐Raso A, Gavín O, Gayol MC, Gil‐Díaz A, Gómez V, Gómez‐Cuervo C, González‐Martínez J, Grau E, Gutiérrez J, Hernández‐Blasco LM, Iglesias M, Jara‐Palomares L, Jaras MJ, Jiménez R, Jiménez‐Castro D, Jiménez‐López J, Joya MD, Lima J, Llamas P, Lobo JL, López‐Jiménez L, López‐Miguel P, López‐Núñez JJ, López‐Reyes R, López‐Sáez JB, Lorente MA, Lorenzo A, Loring M, Madridano O, Maestre A, Martín del Pozo M, Martín‐Guerra JM, Martín‐Romero M, Mellado M, Morales MV, Muñoz N, Nieto‐Cabrera MA, Nieto‐Rodríguez JA, Núñez‐Ares A, Núñez MJ, Olivares MC, Otalora S, Otero R, Pedrajas JM, Pellejero G, Pérez‐Rus G, Peris ML, Porras JA, Rivas A, Rodríguez‐Dávila MA, Rodríguez‐Hernández A, Rubio CM, Ruiz‐Artacho P, Ruiz‐Ruiz J, Ruiz‐Torregrosa P, Ruiz‐Sada P, Sahuquillo JC, Salazar V, Sampériz A, Sánchez‐Muñoz‐Torrero JF, Sancho T, Soler S, Sopeña B, Suriñach JM, Tolosa C, Torres MI, Trujillo‐Santos J, Uresandi F, Valle R, Vidal G, Villares P, Gutiérrez P, Vázquez FJ, Vilaseca A, Vanassche T, Vandenbriele C, Hirmerova J, Malý R, Salgado E, Benzidia I, Bertoletti L, Debourdeau P, Farge‐Bancel D, Hij A, Moustafa F, Schellong S, Braester A, Brenner B, Tzoran I, Sharif‐Kashani B, Bilora F, Bortoluzzi C, Bucherini E, Ciammaichella M, Dentali F, Di Micco P, Di Pangrazio M, Maida R, Mastroiacovo D, Pace F, Pallotti G, Parisi R, Pesavento R, Prandoni P, Quintavalla R, Rocci A, Siniscalchi C, Tufano A, Visonà A, Vo Hong N, Gibietis V, Skride A, Strautmane S, Bosevski M, Zdraveska M, Bounameaux H, Fresa M, Ney B, Caprini J, Bui HM, Pham KQ. D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry. J Intern Med 2020; 287:32-41. [PMID: 31394000 DOI: 10.1111/joim.12969] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND Patients with venous thromboembolism (VTE) secondary to transient risk factors may develop VTE recurrences after discontinuing anticoagulation. Identifying at-risk patients could help to guide the duration of therapy. METHODS We used the RIETE database to assess the prognostic value of d-dimer testing after discontinuing anticoagulation to identify patients at increased risk for recurrences. Transient risk factors were classified as major (postoperative) or minor (pregnancy, oestrogen use, immobilization or recent travel). RESULTS In December 2018, 1655 VTE patients with transient risk factors (major 460, minor 1195) underwent d-dimer measurements after discontinuing anticoagulation. Amongst patients with major risk factors, the recurrence rate was 5.74 (95% CI: 3.19-9.57) events per 100 patient-years in those with raised d-dimer levels and 2.68 (95% CI: 1.45-4.56) in those with normal levels. Amongst patients with minor risk factors, the rates were 7.79 (95% CI: 5.71-10.4) and 3.34 (95% CI: 2.39-4.53), respectively. Patients with major risk factors and raised d-dimer levels (n = 171) had a nonsignificantly higher rate of recurrences (hazard ratio [HR]: 2.14; 95% CI: 0.96-4.79) than those with normal levels. Patients with minor risk factors and raised d-dimer levels (n = 382) had a higher rate of recurrences (HR: 2.34; 95% CI: 1.51-3.63) than those with normal levels. On multivariate analysis, raised d-dimers (HR: 1.74; 95% CI: 1.09-2.77) were associated with an increased risk for recurrences in patients with minor risk factors, not in those with major risk factors. CONCLUSIONS Patients with raised d-dimer levels after discontinuing anticoagulant therapy for VTE provoked by a minor transient risk factor were at an increased risk for recurrences.
Collapse
|
112
|
Martellosio JP, Barra A, Roy-Peaud F, Souchaud-Debouverie O, Martin M, Lateur C, Gombert JM, Roblot P, Puyade M. Performance diagnostique des rapports κ/λ des chaines légères libres sériques (test Freelite®) et IgGκ/IgGλ (test Hevylite®) comme marqueurs pronostiques de chronicisation du purpura thrombopénique immunologique de l’adulte. Rev Med Interne 2020; 41:3-7. [DOI: 10.1016/j.revmed.2019.10.333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2019] [Revised: 10/08/2019] [Accepted: 10/21/2019] [Indexed: 10/25/2022]
|
113
|
Pilmis B, Billard-Pomares T, Martin M, Clarempuy C, Lemezo C, Saint-Marc C, Bourlon N, Seytre D, Carbonnelle E, Zahar JR. Can environmental contamination be explained by particular traits associated with patients? J Hosp Infect 2019; 104:293-297. [PMID: 31870885 DOI: 10.1016/j.jhin.2019.12.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Accepted: 12/12/2019] [Indexed: 12/12/2022]
Abstract
BACKGROUND Little is known about patient risk factors associated with environmental contamination. AIM To evaluate the rate of environmental contamination and to investigate individual risk factors. METHODS A prospective cohort study was conducted. Each day, five rooms occupied by patients were selected. Five critical surfaces were systematically swabbed twice a day before and after cleaning. Clinical characteristics of all patients were collected. Logisitic regression was performed to evaluate the association between environmental contamination and patients' characteristics. FINDINGS A total of 107 consecutive patients were included and 1052 environmental samples were performed. Nineteen (18%) patients were known previously colonized/infected with a multidrug-resistant organism (MDRO). Respectively, 723 (69%) and 112 (11%) samples grew with ≥1 and >2.5 cfu/cm2 bacteria, resulting in 62 (58%) contaminated rooms. Considering positive samples with at least one pathogenic bacterium, 16 (15%) rooms were contaminated. By univariate and multivariate analysis, no variables analysed were associated with the environmental contamination. Considering contaminated rooms with >2.5 cfu/cm2, three factors were protective for environmental contamination: known MDRO carriers/infected patients (odds ratio: 0.25; 95% confidence interval: 0.09-0.72; P = 0.01), patients with urinary catheter (0.19; 0.04-0.89; P = 0.03) and hospitalization in single room (0.3; 0.15-0.6; P < 0.001). CONCLUSION This study was conducted in a non-outbreak situation and showed a low rate of environmental contamination with pathogenic bacteria. Only 11% of environmental samples grew with >2.5 cfu/cm2, and they were related to non-pathogenic bacteria. No risk factors associated with environmental contamination were identified.
Collapse
|
114
|
Schwab C, Höweling A, Windmüller A, Gonzalez-Julian J, Möller S, Binder JR, Uhlenbruck S, Guillon O, Martin M. Bulk and grain boundary Li-diffusion in dense LiMn 2O 4 pellets by means of isotope exchange and ToF-SIMS analysis. Phys Chem Chem Phys 2019; 21:26066-26076. [PMID: 31746869 DOI: 10.1039/c9cp05128g] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Lithium diffusion in LiMn2O4 pellets is studied by means of isotope exchange and Time-of-Flight Secondary Ion Mass Spectrometry (ToF-SIMS). A 6Li-enriched film deposited by Pulsed Laser Deposition (PLD) on a dense LiMn2O4 pellet with natural abundance of lithium isotopes is used to study the tracer diffusion of lithium. The measured profiles are analyzed by numerical models describing the 6Li tracer diffusion from the film into the pellet. Experiments in the Harrison type B regime of diffusion kinetics allow for the distinction and simultaneous determination of bulk and grain boundary diffusion coefficients. Changing the experimental conditions to reach Harrison type A behavior yields effective diffusion coefficients for lithium tracer diffusion in LiMn2O4. Activation energies for bulk and grain boundary diffusion were obtained from experiments at different temperatures. Our values are critically compared to previous studies.
Collapse
|
115
|
Rolland M, Fontanelle J, Puyade M, Landron C, Roblot P, Martin M. Tularémie. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.10.304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
116
|
Joos M, Gasparini S, Landron C, Souchaud-Debouverie O, Roblot P, Martin M. Ce n’est pas le bon cheval ! Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.10.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
117
|
Martellosio J, Puyade M, Elsendoorn A, Souchaud-Debouverie O, Roblot P, Martin M. Rendement diagnostique de la biopsie ostéo-médullaire en médecine interne : étude rétrospective monocentrique de 506 cas. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.10.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
118
|
Marquez-Rodas I, Longo F, Aix SP, Jove M, Rubio B, Blanco AC, Rodriguez-Ruiz M, Ponz-Sarvise M, Castañon E, Gajate P, Sempere-Ortega C, Jimenez-Aguilar E, Lopez-Casas P, de Miguel E, Ramos-Medina R, Calvo A, Martin M, Tersago D, Quintero M, Melero I. Combination of intratumoural double-stranded RNA (dsRNA) BO-112 with systemic anti-PD-1 in patients with anti-PD-1 refractory cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz451.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
119
|
Rugo HS, Diéras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett CHUANG, Iyer S, Johnston S, Ettl J, Harbeck N. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol 2019; 29:888-894. [PMID: 29360932 PMCID: PMC5913649 DOI: 10.1093/annonc/mdy012] [Citation(s) in RCA: 90] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background Patient-reported outcomes are integral in benefit-risk assessments of new treatment regimens. The PALOMA-2 study provides the largest body of evidence for patient-reported health-related quality of life (QOL) for patients with metastatic breast cancer (MBC) receiving first-line endocrine-based therapy (palbociclib plus letrozole and letrozole alone). Patients and methods Treatment-naïve postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) MBC were randomized 2 : 1 to palbociclib plus letrozole (n = 444) or placebo plus letrozole (n = 222). Patient-reported outcomes were assessed at baseline, day 1 of cycles 2 and 3, and day 1 of every other cycle from cycle 5 using the Functional Assessment of Cancer Therapy (FACT)-Breast and EuroQOL 5 dimensions (EQ-5D) questionnaires. Results As of 26 February 2016, the median duration of follow-up was 23 months. Baseline scores were comparable between the two treatment arms. No significant between-arm differences were observed in change from baseline in FACT-Breast Total, FACT-General Total, or EQ-5D scores. Significantly greater improvement in pain scores was observed in the palbociclib plus letrozole arm (-0.256 versus -0.098; P = 0.0183). In both arms, deterioration of FACT-Breast Total score was significantly delayed in patients without progression versus those with progression and patients with partial or complete response versus those without. No significant difference was observed in FACT-Breast and EQ-5D index scores in patients with and without neutropenia. Conclusions Overall, women with MBC receiving first-line endocrine therapy have a good QOL. The addition of palbociclib to letrozole maintains health-related QOL and improves pain scores in treatment-naïve postmenopausal patients with ER+/HER2- MBC compared with letrozole alone. Significantly greater delay in deterioration of health-related QOL was observed in patients without progression versus those who progressed and in patients with an objective response versus non-responders. ClinicalTrials.gov: NCT01740427 (https://clinicaltrials.gov/ct2/show/NCT01740427).
Collapse
|
120
|
Martellosio JP, Lauda-Maillen M, Landron C, Le Moal G, Allouchery M, Arrivé F, Roblot P, Martin M. [Inflammatory myopathy following acute meningoccemia in a properdin-deficient patient: A case report]. Rev Med Interne 2019; 41:46-49. [PMID: 31735371 DOI: 10.1016/j.revmed.2019.10.339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2019] [Revised: 10/18/2019] [Accepted: 10/23/2019] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Myalgia is a classical sign in invasive meningococcal diseases (IMD), but severe and persistent myalgia following an IMD have never been reported to date. CASE REPORT A 20-year-old man presented with purpura fulminans and meningitis caused by Neisseria meningitidis serogroup Y, revealing properdin deficiency. Although meningitis symptoms improved after antibiotherapy, initial myalgia of the lower limbs increased, associated with mild rhabdomyolysis. Magnetic resonance imaging (MRI) revealed an increased STIR (Short TI inversion recovery) signal of both quadriceps muscles, without abscess. After exclusion of other causes of myopathy, a post-infectious myositis was diagnosed. A four-week course of corticosteroids led to dramatic improvement. CONCLUSION Post-infectious inflammatory myopathy should be suspected in case of severe and persistent myalgia associated with rhabdomyolysis following an IMD, after exclusion of pyomyositis especially. A short course of corticosteroids seems to be effective.
Collapse
|
121
|
Segui MA, Cruz JJ, Alba E, Feliu J, Jara C, Rivera F, Rodriguez Lescure A, Lorenzo A, Martin M. Situation, challenges, and SEOM recommendations for the future of undergraduate education in Oncology in Spain. Clin Transl Oncol 2019; 22:1049-1058. [PMID: 31701365 PMCID: PMC7260140 DOI: 10.1007/s12094-019-02230-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2019] [Accepted: 10/17/2019] [Indexed: 11/29/2022]
Abstract
PURPOSE The Spanish Society of Medical Oncology (SEOM, for its Spanish acronym) would like to attest to the relevance of training in Oncology as part of the undergraduate education in Medicine program and issue recommendations to improve said training, with the aim of responding better to the challenges that cancer poses to our society. MATERIALS AND METHODS The curricula of 42 schools of medicine were reviewed with interviews with at least one teaching medical oncologist from each faculty. The qualitative and opinion analysis was completed by means of an online questionnaire targeting lecturers, resident tutors, and residents in Medical Oncology (MO), enabling the detection of needs and areas for improvement at an organizational level and in terms of skill acquisition. RESULTS While the number of medical schools with a specific, mandatory program in MO has grown by up to 90%, it has not been accompanied by an increase in independent programs. Instead, they largely consist of programs shared with other specialties (61% of the medical faculties). In most of the undergraduate education programs, Oncology contents are fragmented and approached from the perspective of each organ system. CONCLUSIONS Despite the positive evolution in recent years, the heterogeneity in Oncology contents during undergraduate education training continues to be remarkable. Cross-sectional programs with an integral vision, taught in the final years of undergraduate medical education would be desirable. Among the recommendations for improvement of training in Medical Oncology, the SEOM proposes that updated, theoretical content be incorporated and clinical practice in Medical Oncology departments be promoted.
Collapse
|
122
|
Lindstrand A, Eisfeldt J, Pettersson M, Carvalho CMB, Kvarnung M, Grigelioniene G, Anderlid BM, Bjerin O, Gustavsson P, Hammarsjö A, Georgii-Hemming P, Iwarsson E, Johansson-Soller M, Lagerstedt-Robinson K, Lieden A, Magnusson M, Martin M, Malmgren H, Nordenskjöld M, Norling A, Sahlin E, Stranneheim H, Tham E, Wincent J, Ygberg S, Wedell A, Wirta V, Nordgren A, Lundin J, Nilsson D. From cytogenetics to cytogenomics: whole-genome sequencing as a first-line test comprehensively captures the diverse spectrum of disease-causing genetic variation underlying intellectual disability. Genome Med 2019; 11:68. [PMID: 31694722 PMCID: PMC6836550 DOI: 10.1186/s13073-019-0675-1] [Citation(s) in RCA: 72] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Accepted: 10/09/2019] [Indexed: 12/30/2022] Open
Abstract
Background Since different types of genetic variants, from single nucleotide variants (SNVs) to large chromosomal rearrangements, underlie intellectual disability, we evaluated the use of whole-genome sequencing (WGS) rather than chromosomal microarray analysis (CMA) as a first-line genetic diagnostic test. Methods We analyzed three cohorts with short-read WGS: (i) a retrospective cohort with validated copy number variants (CNVs) (cohort 1, n = 68), (ii) individuals referred for monogenic multi-gene panels (cohort 2, n = 156), and (iii) 100 prospective, consecutive cases referred to our center for CMA (cohort 3). Bioinformatic tools developed include FindSV, SVDB, Rhocall, Rhoviz, and vcf2cytosure. Results First, we validated our structural variant (SV)-calling pipeline on cohort 1, consisting of three trisomies and 79 deletions and duplications with a median size of 850 kb (min 500 bp, max 155 Mb). All variants were detected. Second, we utilized the same pipeline in cohort 2 and analyzed with monogenic WGS panels, increasing the diagnostic yield to 8%. Next, cohort 3 was analyzed by both CMA and WGS. The WGS data was processed for large (> 10 kb) SVs genome-wide and for exonic SVs and SNVs in a panel of 887 genes linked to intellectual disability as well as genes matched to patient-specific Human Phenotype Ontology (HPO) phenotypes. This yielded a total of 25 pathogenic variants (SNVs or SVs), of which 12 were detected by CMA as well. We also applied short tandem repeat (STR) expansion detection and discovered one pathologic expansion in ATXN7. Finally, a case of Prader-Willi syndrome with uniparental disomy (UPD) was validated in the WGS data. Important positional information was obtained in all cohorts. Remarkably, 7% of the analyzed cases harbored complex structural variants, as exemplified by a ring chromosome and two duplications found to be an insertional translocation and part of a cryptic unbalanced translocation, respectively. Conclusion The overall diagnostic rate of 27% was more than doubled compared to clinical microarray (12%). Using WGS, we detected a wide range of SVs with high accuracy. Since the WGS data also allowed for analysis of SNVs, UPD, and STRs, it represents a powerful comprehensive genetic test in a clinical diagnostic laboratory setting.
Collapse
|
123
|
Vignot S, Martin M, Albin N, Schurtz C, Chapel E. Facilitating access to new therapeutic options through clinical trials: the vision of a regulator to reconcile innovation and safety. Ann Oncol 2019; 30:1694-1696. [PMID: 31501860 DOI: 10.1093/annonc/mdz389] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
124
|
Martin M, Campone M, Bondarenko I, Sakaeva D, Krishnamurthy S, Roman L, Lebedeva L, Vedovato JC, Aapro M. Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane. Ann Oncol 2019; 29:1195-1202. [PMID: 29447329 DOI: 10.1093/annonc/mdy063] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Background Capecitabine is an approved standard therapy for anthracycline- and taxane-pretreated locally advanced or metastatic breast cancer (BC). Vinflunine has demonstrated single-agent activity in phase II studies in this setting and activity and tolerability when combined with capecitabine. We compared the combination of vinflunine plus capecitabine (VC) with single-agent capecitabine. Patients and methods Patients with locally recurrent/metastatic BC previously treated or resistant to an anthracycline and resistant to taxane therapy were randomly assigned to either vinflunine (280 mg/m2, day 1) plus oral capecitabine [825 mg/m2 twice daily (b.i.d.), days 1-14] every 3 weeks (q3w) or single-agent oral capecitabine (1250 mg/m2 b.i.d., days 1-14) q3w. The primary end point was progression-free survival (PFS) assessed by an independent review committee. The study had 90% power to detect a 30% improvement in PFS. Results Overall, 770 patients were randomised. PFS was significantly longer with VC than with capecitabine alone [hazard ratio, 0.84, 95% confidence interval (CI), 0.71-0.99; log-rank P = 0.043; median 5.6 versus 4.3 months, respectively]. Median overall survival was 13.9 versus 11.7 months with VC versus capecitabine alone, respectively (hazard ratio, 0.98; 95% CI, 0.83-1.15; log-rank P = 0.77). No difference in quality of life was observed between the two treatment arms. The most common adverse events (NCI CTCAE version 3.0) in the combination arm were haematological and gastrointestinal. Grade 4 neutropenia was more frequent with VC (12% versus 1% with capecitabine alone); febrile neutropenia occurred in 2% versus 0.5%, respectively. Hand-foot syndrome was less frequent with VC (grade 3: 4% versus 19% for capecitabine alone). Peripheral neuropathy was uncommon in both arms (grade 3: 1% versus 0.3%). Conclusions Vinflunine combined with capecitabine demonstrated a modest improvement in PFS and an acceptable safety profile compared with capecitabine alone in patients with anthracycline- and taxane-pretreated locally recurrent/metastatic BC. ClinicalTrials.gov NCT01095003.
Collapse
|
125
|
Real-Martínez A, Brull A, Huerta J, Villarreal-Salazar M, Tarrasó G, Lucia A, Martin M, Arenas J, Andreu A, Nogales-Gadea G, Vissing J, Krag T, de Luna N, Pinós T. P.119Analysis of the structural and metabolic consequences of McArdle disease using the murine model. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
126
|
Campone M, De Laurentiis M, Zamagni C, Kudryavcev I, Agterof M, Brown-Glaberman U, Palácová M, Chatterjee S, Menon-Singh L, Wu J, Zhou K, Martin M. Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from the CompLEEment-1 trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
127
|
Telford D, Welvaert M, Martin M, Telford R. Drivers of adolescent adiposity: evidence from the Australian look study. J Sci Med Sport 2019. [DOI: 10.1016/j.jsams.2019.08.214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
128
|
Martin M, Atallah V, Prey S, Gérard E, Amestoy F, Benziane N, Leduc N, Huchet A, Beylot-Barry M, Dupin C, Nora O, Dutriaux C, Trouette R, Dousset L, Vendrely V. Radiothérapie concomitante chez des patients pris en charge par immunothérapie pour mélanome avec mutation de B-RAF après thérapie ciblée : étude monocentrique comparative sur 114 patients. Cancer Radiother 2019. [DOI: 10.1016/j.canrad.2019.07.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
129
|
Slamon D, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, Bianchi G, Esteva F, Martin M, Nusch A, Sonke G, De la Cruz-Merino L, Beck J, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez-Lorenc K, Jerusalem G. Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.007] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
130
|
Colombo N, Salerno F, Martin M, Malandrino M, Giardino M, Serra E, Godone D, Said-Pullicino D, Fratianni S, Paro L, Tartari G, Freppaz M. Influence of permafrost, rock and ice glaciers on chemistry of high-elevation ponds (NW Italian Alps). THE SCIENCE OF THE TOTAL ENVIRONMENT 2019; 685:886-901. [PMID: 31247436 DOI: 10.1016/j.scitotenv.2019.06.233] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/20/2019] [Revised: 06/14/2019] [Accepted: 06/15/2019] [Indexed: 06/09/2023]
Abstract
Permafrost degradation, rock-glacier thawing, and glacier retreat are influencing surface water quality at high elevations. However, there is a lack of knowledge on the dominant geochemical reactions occurring in different cryospheric conditions and how these reactions change during the ice-free season. In the Col d'Olen area (LTER site, NW Italian Alps), four ponds with similar sizes, located in basins with different cryospheric features (glacier, permafrost, rock glacier, none of these), are present in a geographically limited area. All ponds were sampled weekly in 2015 and partially in 2014. Major ions, selected trace elements, and biotic parameters (dissolved organic carbon-DOC, fluorescence index-FI, and nitrate) are examined to evidence the effect of different cryospheric features on water characteristics. Where cryospheric conditions occur chemical weathering is more intensive, with strong seasonal increase of major ions. Sulphide oxidation dominates in glacier and permafrost lying on acid rocks, probably driven by enhanced weathering of freshly exposed rocks in subglacial environment and recently deglaciated areas, and active layer thickness increase. Differently, carbonation dominates for the rock glacier lying on ultramafic rocks. There, high Ni concentrations originate from dissolution of Mg-bearing rocks in the landform. In all settings, pH neutralisation occurs because of the presence of secondary carbonate lithology and ultramafic rocks. Nitrate highest concentrations and changes occur in cryospheric settings while DOC and FI do not show strong differences and seasonal variations. The establishment of more frequent monitoring for water quality in high-elevated surface waters is necessary to provide greater statistical power to detect changes on longer time scales.
Collapse
|
131
|
Ots PMS, Ocaña CV, Martin M, Álvarez FJC, Albiol DF, Oses MR, Flamarique S, Ruperto FR, Serrano CMB, Gomez LLG, Alcantara M, Villar MJR, Antón JLM, Bueno PS, Tirado FJL, Puertas M, Bobo A, De Cerio ID, Gascon N, Albiach C. Stereotactic Body Radiotherapy for Early Stage Lung Cancer: A Multicentric Study. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
132
|
Mania I, Gorra R, Colombo N, Freppaz M, Martin M, Anesio AM. Prokaryotic Diversity and Distribution in Different Habitats of an Alpine Rock Glacier-Pond System. MICROBIAL ECOLOGY 2019; 78:70-84. [PMID: 30317429 DOI: 10.1007/s00248-018-1272-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Accepted: 10/04/2018] [Indexed: 06/08/2023]
Abstract
Rock glaciers (RG) are assumed to influence the biogeochemistry of downstream ecosystems because of the high ratio of rock:water in those systems, but no studies have considered the effects of a RG inflow on the microbial ecology of sediments in a downstream pond. An alpine RG-pond system, located in the NW Italian Alps has been chosen as a model, and Bacteria and Archaea 16S rRNA genes abundance, distribution and diversity have been assessed by qPCR and Illumina sequencing, coupled with geochemical analyses on sediments collected along a distance gradient from the RG inflow. RG surface material and neighbouring soil have been included in the analysis to better elucidate relationships among different habitats.Our results showed that different habitats harboured different, well-separated microbial assemblages. Across the pond, the main variations in community composition (e.g. Thaumarchaeota and Cyanobacteria relative abundance) and porewater geochemistry (pH, DOC, TDN and NH4+) were not directly linked to RG proximity, but to differences in water depth. Some microbial markers potentially linked to the presence of meltwater inputs from the RG have been recognised, although the RG seems to have a greater influence on the pond microbial communities due to its contribution in terms of sedimentary material.
Collapse
|
133
|
Reginster JY, Bianic F, Campbell R, Martin M, Williams SA, Fitzpatrick LA. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int 2019; 30:1465-1473. [PMID: 30953114 PMCID: PMC6614166 DOI: 10.1007/s00198-019-04947-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Accepted: 03/18/2019] [Indexed: 02/07/2023]
Abstract
UNLABELLED This network meta-analysis assessed the efficacy of abaloparatide versus other treatment options to reduce the risk of fractures in women with postmenopausal osteoporosis. The analysis indicates that abaloparatide reduces the risk of fractures in women with postmenopausal osteoporosis versus placebo and compared with other treatment options. INTRODUCTION This network meta-analysis (NMA) assessed the relative efficacy of abaloparatide versus other treatments to reduce the risk of fractures in women with postmenopausal osteoporosis (PMO). METHODS PubMed®, Embase®, and the Cochrane Central Register of Controlled Trials were searched for randomized controlled trials published before December 20, 2017, that included women with PMO who were eligible to receive interventions for primary or secondary fracture prevention. The NMA was conducted by fracture site (vertebral [VF], nonvertebral [NVF], and wrist), with the relative risk (RR) of fracture versus placebo the main clinical endpoint. The NMA used fixed-effects and random-effects approaches. RESULTS A total of 4978 articles were screened, of which 22 were included in the analysis. Compared with other treatments, abaloparatide demonstrated the greatest treatment effect relative to placebo in the VF network (RR = 0.13; 95% credible interval [CrI] 0.04-0.34), the NVF network (RR = 0.50; 95% CrI 0.28-0.85), and the wrist fracture network (RR = 0.39; CrI 0.15-0.90). Treatment ranking showed that abaloparatide had the highest estimated probability of preventing fractures in each of the networks (79% for VF, 70% for NVF, and 53% for wrist fracture) compared with other treatments. Individual networks demonstrated a good level of agreement with direct trial evidence and direct pair-wise comparisons. CONCLUSIONS This NMA indicates that abaloparatide reduces the RR of VF, NVF, and wrist fracture in women with PMO with or without prior fracture versus placebo, compared with other treatment options. Limitations include that adverse events and drug costs were not considered, and that generalizability is limited to the trial populations and endpoints included in the NMA.
Collapse
|
134
|
Caracciolo AB, Dejana L, Fajardo C, Grenni P, Martin M, Mengs G, Sánchez-Fortún S, Lettieri T, Saccà M, Medlin L. A new fluorescent oligonucleotide probe for in-situ identification of Microcystis aeruginosa in freshwater. Microchem J 2019. [DOI: 10.1016/j.microc.2019.05.017] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
135
|
Picornell AC, Echavarria I, Alvarez E, López-Tarruella S, Jerez Y, Hoadley K, Parker JS, Del Monte-Millán M, Ramos-Medina R, Gayarre J, Ocaña I, Cebollero M, Massarrah T, Moreno F, García Saenz JA, Gómez Moreno H, Ballesteros A, Ruiz Borrego M, Perou CM, Martin M. Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series. BMC Genomics 2019; 20:452. [PMID: 31159741 PMCID: PMC6547580 DOI: 10.1186/s12864-019-5849-0] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2018] [Accepted: 05/27/2019] [Indexed: 01/18/2023] Open
Abstract
Background Full RNA-Seq is a fundamental research tool for whole transcriptome analysis. However, it is too costly and time consuming to be used in routine clinical practice. We evaluated the transcript quantification agreement between RNA-Seq and a digital multiplexed gene expression platform, and the subtype call after running the PAM50 assay in a series of breast cancer patients classified as triple negative by IHC/FISH. The goal of this study is to analyze the concordance between both expression platforms overall, and for calling PAM50 triple negative breast cancer intrinsic subtypes in particular. Results The analyses were performed in paraffin-embedded tissues from 96 patients recruited in a multicenter, prospective, non-randomized neoadjuvant triple negative breast cancer trial (NCT01560663). Pre-treatment core biopsies were obtained following clinical practice guidelines and conserved as FFPE for further RNA extraction. PAM50 was performed on both digital multiplexed gene expression and RNA-Seq platforms. Subtype assignment was based on the nearest centroid classification following this procedure for both platforms and it was concordant on 96% of the cases (N = 96). In four cases, digital multiplexed gene expression analysis and RNA-Seq were discordant. The Spearman correlation to each of the centroids and the risk of recurrence were above 0.89 in both platforms while the agreement on Proliferation Score reached up to 0.97. In addition, 82% of the individual PAM50 genes showed a correlation coefficient > 0.80. Conclusions In our analysis, the subtype calling in most of the samples was concordant in both platforms and the potential discordances had reduced clinical implications in terms of prognosis. If speed and cost are the main driving forces then the preferred technique is the digital multiplexed platform, while if whole genome patterns and subtype are the driving forces, then RNA-Seq is the preferred method. Electronic supplementary material The online version of this article (10.1186/s12864-019-5849-0) contains supplementary material, which is available to authorized users.
Collapse
|
136
|
Freue J, Ostriz BR, Martin M, Campestri R. PS1098 ADULT ONSET HEREDITARY THROMBOTIC THROMBOCYTOPENIC PURPURA WITH A NOVEL ADAMTS13 MUTATION. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000562684.56755.87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
137
|
Liberatore J, Landron C, Roblot P, Allouchery M, Haroche J, Martin M. Erdheim Chester, quand les anticorps s’en mêlent. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.03.235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
138
|
Martin M, Pivonka P, Haïat G, Sansalone V, Lemaire T. An enriched continuum mechanics description of bone tissue to describe mineralization and mechanobiology in bone remodeling. Comput Methods Biomech Biomed Engin 2019. [DOI: 10.1080/10255842.2020.1713484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
139
|
Martellosio JP, Leleu X, Roblot P, Martin M, Puyade M. Dosage des chaînes légères libres : indications et méthodes. Rev Med Interne 2019; 40:297-305. [DOI: 10.1016/j.revmed.2019.01.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Revised: 01/04/2019] [Accepted: 01/20/2019] [Indexed: 12/18/2022]
|
140
|
Teng C, Lekwuttikarn R, Tafoya E, Martin M, Bruckner A, Mancini A, Stell L, Lu Y, Teng J. 388 A multicenter study on the use of Sildenafil for lymphatic malformation in children. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
141
|
Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, Diéras V, Moulder S, Lipatov O, Colleoni M, Cristofanilli M, Lu DR, Mori A, Giorgetti C, Iyer S, Bartlett CH, Gelmon KA. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann Oncol 2019; 29:669-680. [PMID: 29342248 PMCID: PMC5888946 DOI: 10.1093/annonc/mdx797] [Citation(s) in RCA: 63] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background This report assesses the efficacy and safety of palbociclib plus endocrine therapy (ET) in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC) with or without visceral metastases. Patients and methods Pre- and postmenopausal women with disease progression following prior ET (PALOMA-3; N = 521) and postmenopausal women untreated for ABC (PALOMA-2; N = 666) were randomized 2 : 1 to ET (fulvestrant or letrozole, respectively) plus palbociclib or placebo. Progression-free survival (PFS), safety, and patient-reported quality of life (QoL) were evaluated by prior treatment and visceral involvement. Results Visceral metastases incidence was higher in patients with prior resistance to ET (58.3%, PALOMA-3) than in patients naive to ET in the ABC setting (48.6%, PALOMA-2). In patients with prior resistance to ET and visceral metastases, median PFS (mPFS) was 9.2 months with palbociclib plus fulvestrant versus 3.4 months with placebo plus fulvestrant [hazard ratio (HR), 0.47; 95% confidence interval (CI), 0.35–0.61], and objective response rate (ORR) was 28.0% versus 6.7%, respectively. In patients with nonvisceral metastases, mPFS was 16.6 versus 7.3 months, HR 0.53; 95% CI 0.36–0.77. In patients with visceral disease and naive to ET in the advanced disease setting, mPFS was 19.3 months with palbociclib plus letrozole versus 12.9 months with placebo plus letrozole (HR 0.63; 95% CI 0.47–0.85); ORR was 55.1% versus 40.0%; in patients with nonvisceral disease, mPFS was not reached with palbociclib plus letrozole versus 16.8 months with placebo plus letrozole (HR 0.50; 95% CI 0.36–0.70). In patients with prior resistance to ET with visceral metastases, palbociclib plus fulvestrant significantly delayed deterioration of QoL versus placebo plus fulvestrant, whereas patient-reported QoL was maintained with palbociclib plus letrozole in patients naive to endocrine-based therapy for ABC. Conclusions Palbociclib plus ET prolonged mPFS in patients with visceral metastases, increased ORRs, and in patients previously treated for ABC, delayed QoL deterioration, presenting a standard treatment option among patients with visceral metastases amenable to endocrine-based therapy. Clinical trial registration NCT01942135, NCT01740427
Collapse
|
142
|
Vázquez Bernat N, Corcoran M, Hardt U, Kaduk M, Phad GE, Martin M, Karlsson Hedestam GB. High-Quality Library Preparation for NGS-Based Immunoglobulin Germline Gene Inference and Repertoire Expression Analysis. Front Immunol 2019; 10:660. [PMID: 31024532 PMCID: PMC6459949 DOI: 10.3389/fimmu.2019.00660] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Accepted: 03/11/2019] [Indexed: 12/13/2022] Open
Abstract
Next generation sequencing (NGS) of immunoglobulin (Ig) repertoires (Rep-seq) enables examination of the adaptive immune system at an unprecedented level. Applications include studies of expressed repertoires, gene usage, somatic hypermutation levels, Ig lineage tracing and identification of genetic variation within the Ig loci through inference methods. All these applications require starting libraries that allow the generation of sequence data with low error rate and optimal representation of the expressed repertoire. Here, we provide detailed protocols for the production of libraries suitable for human Ig germline gene inference and Ig repertoire studies. Various parameters used in the process were tested in order to demonstrate factors that are critical to obtain high quality libraries. We demonstrate an improved 5'RACE technique that reduces the length constraints of Illumina MiSeq based Rep-seq analysis but allows for the acquisition of sequences upstream of Ig V genes, useful for primer design. We then describe a 5' multiplex method for library preparation, which yields full length V(D)J sequences suitable for genotype identification and novel gene inference. We provide comprehensive sets of primers targeting IGHV, IGKV, and IGLV genes. Using the optimized protocol, we produced IgM, IgG, IgK, and IgL libraries and analyzed them using the germline inference tool IgDiscover to identify expressed germline V alleles. This process additionally uncovered three IGHV, one IGKV, and six IGLV novel alleles in a single individual, which are absent from the IMGT reference database, highlighting the need for further study of Ig genetic variation. The library generation protocols presented here enable a robust means of analyzing expressed Ig repertoires, identifying novel alleles and producing individualized germline gene databases from humans.
Collapse
|
143
|
Aaij R, Adeva B, Adinolfi M, Aidala CA, Ajaltouni Z, Akar S, Albicocco P, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Ali S, Alkhazov G, Alvarez Cartelle P, Alves AA, Amato S, Amerio S, Amhis Y, An L, Anderlini L, Andreassi G, Andreotti M, Andrews JE, Appleby RB, Archilli F, d'Argent P, Arnau Romeu J, Artamonov A, Artuso M, Arzymatov K, Aslanides E, Atzeni M, Audurier B, Bachmann S, Back JJ, Baker S, Balagura V, Baldini W, Baranov A, Barlow RJ, Barsuk S, Barter W, Baryshnikov F, Batozskaya V, Batsukh B, Battista V, Bay A, Beddow J, Bedeschi F, Bediaga I, Beiter A, Bel LJ, Belin S, Beliy N, Bellee V, Belloli N, Belous K, Belyaev I, Ben-Haim E, Bencivenni G, Benson S, Beranek S, Berezhnoy A, Bernet R, Berninghoff D, Bertholet E, Bertolin A, Betancourt C, Betti F, Bettler MO, van Beuzekom M, Bezshyiko I, Bhasin S, Bhom J, Bifani S, Billoir P, Birnkraut A, Bizzeti A, Bjørn M, Blago MP, Blake T, Blanc F, Blusk S, Bobulska D, Bocci V, Boente Garcia O, Boettcher T, Bondar A, Bondar N, Borghi S, Borisyak M, Borsato M, Bossu F, Boubdir M, Bowcock TJV, Bozzi C, Braun S, Brodski M, Brodzicka J, Brossa Gonzalo A, Brundu D, Buchanan E, Buonaura A, Burr C, Bursche A, Buytaert J, Byczynski W, Cadeddu S, Cai H, Calabrese R, Calladine R, Calvi M, Calvo Gomez M, Camboni A, Campana P, Campora Perez DH, Capriotti L, Carbone A, Carboni G, Cardinale R, Cardini A, Carniti P, Carson L, Carvalho Akiba K, Casse G, Cassina L, Cattaneo M, Cavallero G, Cenci R, Chamont D, Chapman MG, Charles M, Charpentier P, Chatzikonstantinidis G, Chefdeville M, Chekalina V, Chen C, Chen S, Chitic SG, Chobanova V, Chrzaszcz M, Chubykin A, Ciambrone P, Cid Vidal X, Ciezarek G, Clarke PEL, Clemencic M, Cliff HV, Closier J, Coco V, Coelho JAB, Cogan J, Cogneras E, Cojocariu L, Collins P, Colombo T, Comerma-Montells A, Contu A, Coombs G, Coquereau S, Corti G, Corvo M, Costa Sobral CM, Couturier B, Cowan GA, Craik DC, Crocombe A, Cruz Torres M, Currie R, D'Ambrosio C, Da Cunha Marinho F, Da Silva CL, Dall'Occo E, Dalseno J, Danilina A, Davis A, De Aguiar Francisco O, De Bruyn K, De Capua S, De Cian M, De Miranda JM, De Paula L, De Serio M, De Simone P, Dean CT, Decamp D, Del Buono L, Delaney B, Dembinski HP, Demmer M, Dendek A, Derkach D, Deschamps O, Desse F, Dettori F, Dey B, Di Canto A, Di Nezza P, Didenko S, Dijkstra H, Dordei F, Dorigo M, Dosil Suárez A, Douglas L, Dovbnya A, Dreimanis K, Dufour L, Dujany G, Durante P, Durham JM, Dutta D, Dzhelyadin R, Dziewiecki M, Dziurda A, Dzyuba A, Easo S, Egede U, Egorychev V, Eidelman S, Eisenhardt S, Eitschberger U, Ekelhof R, Eklund L, Ely S, Ene A, Escher S, Esen S, Evans T, Falabella A, Farley N, Farry S, Fazzini D, Federici L, Fernandez Declara P, Fernandez Prieto A, Ferrari F, Ferreira Lopes L, Ferreira Rodrigues F, Ferro-Luzzi M, Filippov S, Fini RA, Fiorini M, Firlej M, Fitzpatrick C, Fiutowski T, Fleuret F, Fontana M, Fontanelli F, Forty R, Franco Lima V, Frank M, Frei C, Fu J, Funk W, Färber C, Féo M, Gabriel E, Gallas Torreira A, Galli D, Gallorini S, Gambetta S, Gan Y, Gandelman M, Gandini P, Gao Y, Garcia Martin LM, Garcia Plana B, García Pardiñas J, Garra Tico J, Garrido L, Gascon D, Gaspar C, Gavardi L, Gazzoni G, Gerick D, Gersabeck E, Gersabeck M, Gershon T, Gerstel D, Ghez P, Gianì S, Gibson V, Girard OG, Giubega L, Gizdov K, Gligorov VV, Golubkov D, Golutvin A, Gomes A, Gorelov IV, Gotti C, Govorkova E, Grabowski JP, Graciani Diaz R, Granado Cardoso LA, Graugés E, Graverini E, Graziani G, Grecu A, Greim R, Griffith P, Grillo L, Gruber L, Gruberg Cazon BR, Grünberg O, Gu C, Gushchin E, Guz Y, Gys T, Göbel C, Hadavizadeh T, Hadjivasiliou C, Haefeli G, Haen C, Haines SC, Hamilton B, Han X, Hancock TH, Hansmann-Menzemer S, Harnew N, Harnew ST, Harrison T, Hasse C, Hatch M, He J, Hecker M, Heinicke K, Heister A, Hennessy K, Henry L, van Herwijnen E, Heß M, Hicheur A, Hidalgo Charman R, Hill D, Hilton M, Hopchev PH, Hu W, Huang W, Huard ZC, Hulsbergen W, Humair T, Hushchyn M, Hutchcroft D, Hynds D, Ibis P, Idzik M, Ilten P, Ivshin K, Jacobsson R, Jalocha J, Jans E, Jawahery A, Jiang F, John M, Johnson D, Jones CR, Joram C, Jost B, Jurik N, Kandybei S, Karacson M, Kariuki JM, Karodia S, Kazeev N, Kecke M, Keizer F, Kelsey M, Kenzie M, Ketel T, Khairullin E, Khanji B, Khurewathanakul C, Kim KE, Kirn T, Klaver S, Klimaszewski K, Klimkovich T, Koliiev S, Kolpin M, Kopecna R, Koppenburg P, Kostiuk I, Kotriakhova S, Kozeiha M, Kravchuk L, Kreps M, Kress F, Krokovny P, Krupa W, Krzemien W, Kucewicz W, Kucharczyk M, Kudryavtsev V, Kuonen AK, Kvaratskheliya T, Lacarrere D, Lafferty G, Lai A, Lancierini D, Lanfranchi G, Langenbruch C, Latham T, Lazzeroni C, Le Gac R, Leflat A, Lefrançois J, Lefèvre R, Lemaitre F, Leroy O, Lesiak T, Leverington B, Li PR, Li T, Li Z, Liang X, Likhomanenko T, Lindner R, Lionetto F, Lisovskyi V, Liu X, Loh D, Loi A, Longstaff I, Lopes JH, Lovell GH, Lucchesi D, Lucio Martinez M, Lupato A, Luppi E, Lupton O, Lusiani A, Lyu X, Machefert F, Maciuc F, Macko V, Mackowiak P, Maddrell-Mander S, Maev O, Maguire K, Maisuzenko D, Majewski MW, Malde S, Malecki B, Malinin A, Maltsev T, Manca G, Mancinelli G, Marangotto D, Maratas J, Marchand JF, Marconi U, Marin Benito C, Marinangeli M, Marino P, Marks J, Marshall PJ, Martellotti G, Martin M, Martinelli M, Martinez Santos D, Martinez Vidal F, Massafferri A, Materok M, Matev R, Mathad A, Mathe Z, Matteuzzi C, Mauri A, Maurice E, Maurin B, Mazurov A, McCann M, McNab A, McNulty R, Mead JV, Meadows B, Meaux C, Meier F, Meinert N, Melnychuk D, Merk M, Merli A, Michielin E, Milanes DA, Millard E, Minard MN, Minzoni L, Mitzel DS, Mogini A, Molina Rodriguez J, Mombächer T, Monroy IA, Monteil S, Morandin M, Morello G, Morello MJ, Morgunova O, Moron J, Morris AB, Mountain R, Muheim F, Mulder M, Murphy CH, Murray D, Mödden A, Müller D, Müller J, Müller K, Müller V, Naik P, Nakada T, Nandakumar R, Nandi A, Nanut T, Nasteva I, Needham M, Neri N, Neubert S, Neufeld N, Neuner M, Nguyen TD, Nguyen-Mau C, Nieswand S, Niet R, Nikitin N, Nogay A, Nolte NS, O'Hanlon DP, Oblakowska-Mucha A, Obraztsov V, Ogilvy S, Oldeman R, Onderwater CJG, Ossowska A, Otalora Goicochea JM, Owen P, Oyanguren A, Pais PR, Pajero T, Palano A, Palutan M, Panshin G, Papanestis A, Pappagallo M, Pappalardo LL, Parker W, Parkes C, Passaleva G, Pastore A, Patel M, Patrignani C, Pearce A, Pellegrino A, Penso G, Pepe Altarelli M, Perazzini S, Pereima D, Perret P, Pescatore L, Petridis K, Petrolini A, Petrov A, Petrucci S, Petruzzo M, Pietrzyk B, Pietrzyk G, Pikies M, Pili M, Pinci D, Pinzino J, Pisani F, Piucci A, Placinta V, Playfer S, Plews J, Plo Casasus M, Polci F, Poli Lener M, Poluektov A, Polukhina N, Polyakov I, Polycarpo E, Pomery GJ, Ponce S, Popov A, Popov D, Poslavskii S, Potterat C, Price E, Prisciandaro J, Prouve C, Pugatch V, Puig Navarro A, Pullen H, Punzi G, Qian W, Qin J, Quagliani R, Quintana B, Rachwal B, Rademacker JH, Rama M, Ramos Pernas M, Rangel MS, Ratnikov F, Raven G, Ravonel Salzgeber M, Reboud M, Redi F, Reichert S, Dos Reis AC, Reiss F, Remon Alepuz C, Ren Z, Renaudin V, Ricciardi S, Richards S, Rinnert K, Robbe P, Robert A, Rodrigues AB, Rodrigues E, Rodriguez Lopez JA, Roehrken M, Rogozhnikov A, Roiser S, Rollings A, Romanovskiy V, Romero Vidal A, Rotondo M, Rudolph MS, Ruf T, Ruiz Vidal J, Saborido Silva JJ, Sagidova N, Saitta B, Salustino Guimaraes V, Sanchez Gras C, Sanchez Mayordomo C, Sanmartin Sedes B, Santacesaria R, Santamarina Rios C, Santimaria M, Santovetti E, Sarpis G, Sarti A, Satriano C, Satta A, Saur M, Savrina D, Schael S, Schellenberg M, Schiller M, Schindler H, Schmelling M, Schmelzer T, Schmidt B, Schneider O, Schopper A, Schreiner HF, Schubiger M, Schune MH, Schwemmer R, Sciascia B, Sciubba A, Semennikov A, Sepulveda ES, Sergi A, Serra N, Serrano J, Sestini L, Seuthe A, Seyfert P, Shapkin M, Shcheglov Y, Shears T, Shekhtman L, Shevchenko V, Shmanin E, Siddi BG, Silva Coutinho R, Silva de Oliveira L, Simi G, Simone S, Skidmore N, Skwarnicki T, Smeaton JG, Smith E, Smith IT, Smith M, Soares M, Soares Lavra L, Sokoloff MD, Soler FJP, Souza De Paula B, Spaan B, Spradlin P, Stagni F, Stahl M, Stahl S, Stefko P, Stefkova S, Steinkamp O, Stemmle S, Stenyakin O, Stepanova M, Stevens H, Stocchi A, Stone S, Storaci B, Stracka S, Stramaglia ME, Straticiuc M, Straumann U, Strokov S, Sun J, Sun L, Swientek K, Syropoulos V, Szumlak T, Szymanski M, T'Jampens S, Tang Z, Tayduganov A, Tekampe T, Tellarini G, Teubert F, Thomas E, van Tilburg J, Tilley MJ, Tisserand V, Tobin M, Tolk S, Tomassetti L, Tonelli D, Tou DY, Tourinho Jadallah Aoude R, Tournefier E, Traill M, Tran MT, Trisovic A, Tsaregorodtsev A, Tuci G, Tully A, Tuning N, Ukleja A, Usachov A, Ustyuzhanin A, Uwer U, Vagner A, Vagnoni V, Valassi A, Valat S, Valenti G, Vazquez Gomez R, Vazquez Regueiro P, Vecchi S, van Veghel M, Velthuis JJ, Veltri M, Veneziano G, Venkateswaran A, Verlage TA, Vernet M, Veronesi M, Veronika NV, Vesterinen M, Viana Barbosa JV, Vieira D, Vieites Diaz M, Viemann H, Vilasis-Cardona X, Vitkovskiy A, Vitti M, Volkov V, Vollhardt A, Voneki B, Vorobyev A, Vorobyev V, de Vries JA, Vázquez Sierra C, Waldi R, Walsh J, Wang J, Wang M, Wang Y, Wang Z, Ward DR, Wark HM, Watson NK, Websdale D, Weiden A, Weisser C, Whitehead M, Wicht J, Wilkinson G, Wilkinson M, Williams I, Williams MRJ, Williams M, Williams T, Wilson FF, Wimberley J, Winn M, Wishahi J, Wislicki W, Witek M, Wormser G, Wotton SA, Wyllie K, Xiao D, Xie Y, Xu A, Xu M, Xu Q, Xu Z, Xu Z, Yang Z, Yang Z, Yao Y, Yeomans LE, Yin H, Yu J, Yuan X, Yushchenko O, Zarebski KA, Zavertyaev M, Zhang D, Zhang L, Zhang WC, Zhang Y, Zhelezov A, Zheng Y, Zhu X, Zhukov V, Zonneveld JB, Zucchelli S. First Measurement of Charm Production in its Fixed-Target Configuration at the LHC. PHYSICAL REVIEW LETTERS 2019; 122:132002. [PMID: 31012627 DOI: 10.1103/physrevlett.122.132002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/19/2018] [Revised: 02/01/2019] [Indexed: 06/09/2023]
Abstract
The first measurement of heavy-flavor production by the LHCb experiment in its fixed-target mode is presented. The production of J/ψ and D^{0} mesons is studied with beams of protons of different energies colliding with gaseous targets of helium and argon with nucleon-nucleon center-of-mass energies of sqrt[s_{NN}]=86.6 and 110.4 GeV, respectively. The J/ψ and D^{0} production cross sections in pHe collisions in the rapidity range [2, 4.6] are found to be σ_{J/ψ}=652±33(stat)±42(syst) nb/nucleon and σ_{D^{0}}=80.8±2.4(stat)±6.3(syst) μb/nucleon, where the first uncertainty is statistical and the second is systematic. No evidence for a substantial intrinsic charm content of the nucleon is observed in the large Bjorken-x region.
Collapse
|
144
|
Benziane N, Atallah V, Amestoy F, Gerard E, Leduc N, Huchet A, Barry MB, Dupin C, Prey S, Dousset L, Ouabrache N, Martin M, Gillon P, Dutriaux C, Trouette R, Vendrely V. EP-1596 Radiotherapy and Ipilimumab as first-line immunotherapy: A comparative study on 63 patients. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32016-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
145
|
De la Pinta Alonso C, Fernández E, Martin M, Hernanz R, Vallejo C, Martín M, Capúz A, Rojo J, Villodre I, Sancho S. PO-0743 Single dose versus FSRT for brain metastases: a retrospective study. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31163-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
146
|
Delaloge S, Cella D, Ye Y, Buyse M, Chan A, Barrios CH, Holmes FA, Mansi J, Iwata H, Ejlertsen B, Moy B, Chia SKL, Gnant M, Smichkoska S, Ciceniene A, Martinez N, Filipović S, Ben-Baruch NE, Joy AA, Langkjer ST, Senecal F, de Boer RH, Moran S, Yao B, Bryce R, Auerbach A, Fallowfield L, Martin M. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. Ann Oncol 2019; 30:567-574. [PMID: 30689703 DOI: 10.1093/annonc/mdz016] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND We report longitudinal health-related quality-of-life (HRQoL) data from the international, randomized, double-blind, placebo-controlled phase III ExteNET study, which demonstrated an invasive disease-free survival benefit of extended adjuvant therapy with neratinib over placebo in human epidermal growth factor receptor-2-positive early-stage breast cancer. PATIENTS AND METHODS Women (N = 2840) with early-stage HER2-positive breast cancer who had completed trastuzumab-based adjuvant therapy were randomly assigned to neratinib 240 mg/day or placebo for 12 months. HRQoL was an exploratory end point. Patients completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) and EuroQol 5-Dimensions (EQ-5D) questionnaires at baseline and months 1, 3, 6, 9, and 12. Changes from baseline were compared using analysis of covariance with no imputation for missing values. Sensitivity analyses used alternative methods. Changes in HRQoL scores were regarded as clinically meaningful if they exceeded previously reported important differences (IDs). RESULTS Of the 2840 patients (intention-to-treat population), 2407 patients were evaluable for FACT-B (neratinib, N = 1171; placebo, N = 1236) and 2427 patients for EQ-5D (neratinib, N = 1186; placebo, N = 1241). Questionnaire completion rates exceeded 85%. Neratinib was associated with a decrease in global HRQoL scores at month 1 compared with placebo (adjusted mean differences: FACT-B total, -2.9 points; EQ-5D index, -0.02), after which between-group differences diminished at later time-points. Except for the FACT-B physical well-being (PWB) subscale at month 1; all between-group differences were less than reported IDs. The FACT-B breast cancer-specific subscale showed small improvements with neratinib at months 3-9, but all were less than IDs. Sensitivity analyses exploring missing data did not change the results. CONCLUSIONS Extended adjuvant neratinib was associated with a transient, reversible decrease in HRQoL during the first month of treatment, possibly linked to treatment-related diarrhea. With the exception of the PWB subscale at month 1, all neratinib-related HRQoL changes did not reach clinically meaningful thresholds. ClinicalTrials.gov: NCT00878709.
Collapse
|
147
|
Jadot V, Segers K, Bours V, Kohnen L, Honoré P, Martin M, De Flines J, Mutijima E, Leclercq P. [Hereditary diffuse gastric cancer : case serie of 8 patients from a single family and literature review]. REVUE MEDICALE DE LIEGE 2019; 74:134-138. [PMID: 30897312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Hereditary diffuse gastric cancer is a form of gastric cancer associated, in about 40 % of cases, with a germline mutation of the CDH1 gene. The management of patients with a pathogenic mutation of this gene is based on total prophylactic gastrectomy because, until proven otherwise, endoscopic monitoring is insufficient. We report a series of eight patients with pathogenic CDH1 mutation who underwent total prophylactic gastrectomy in our centre.
Collapse
|
148
|
Ejlertsen B, Holmes F, Chia S, Iwata H, Moy B, Delaloge S, Xu F, Barnett B, Chan A, Martin M. Efficacy of neratinib in hormone receptor-positive (HR+) patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer (BC): subgroup analyses from the phase III ExteNET trial. Breast 2019. [DOI: 10.1016/s0960-9776(19)30112-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
149
|
Ring A, Borstnar S, Ferreira A, Azim HA, Cottu P, Lu J, Martin M, Zamagni C, Beck JT, Zhou K, Wu J, Menon L, De Laurentiis M. Abstract P6-18-16: Ribociclib (RIBO) + letrozole (LET) in older patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Preliminary subgroup results from the phase 3b CompLEEment-1 trial. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The cyclin-dependent kinase (CDK)4/6 inhibitor RIBO is approved in combination with an aromatase inhibitor (AI) for HR+, HER2– ABC in postmenopausal women with no prior therapy for ABC, based on the MONALEESA-2 trial (Hortobagyi et al. NEJM 2016). Although a high proportion of patients with HR+, HER2– ABC are >65 years of age, older patients are often under-represented in clinical trials. Furthermore, treatment decisions may be complicated by comorbidities, functional status, and concurrent medications. Here, we report early safety results for patients ≥65 years of age enrolled in CompLEEment-1, an open-label, phase 3b trial evaluating RIBO+LET as first-line endocrine-based therapy in an expanded patient population.
Methods: Patients with HR+, HER2– ABC, ≤1 line of prior chemotherapy (CT), and no prior endocrine therapy for ABC received RIBO (600 mg/day, 3 weeks on/1 week off) + LET (2.5 mg/day); men and premenopausal women received concomitant goserelin (3.6-mg subcutaneous implant every 28 days). The primary outcome was safety and tolerability. A pre-planned interim analysis was conducted ˜15 months after first patient first visit.
Results: Of the first 1,008 patients enrolled who completed 56 days of follow-up or discontinued before the data cut-off date, 377 were ≥65 years of age. Of these, 157 (41.6%) were 65-<70 years, 107 (28.4%) were 70-<75 years, and 113 (30%) were ≥75 years. The majority of patients (94.4%) had an Eastern Cooperative Oncology Group performance status ≤1; 33.2% presented with stage IV disease at diagnosis; 9 patients were male. The most common sites of metastasis were bone (70.0%), lung (44.8%), and lymph nodes (29.7%). The most common all-grade adverse events (AEs) were neutropenia (58.4%), nausea (31.8%), and fatigue (24.1%). The most common grade 3/4 AEs were neutropenia (37.7%) and alanine aminotransferase increase (4.2%). QT prolongation events were mild (majority grade 1/2) and occurred in 6.1% of patients (0.5% grade 3/4). Dose reduction or interruption due to AEs occurred in 54.5% of patients; 6.9% of patients had AEs leading to treatment discontinuation. In the overall patient population, the most frequent grade 3/4 AEs were neutropenia (42.8%), leukopenia (3.4%), and increased alanine aminotransferase (2.9%); QT prolongation occurred in 5.4% of patients (0.5% grade 3/4).
Conclusions: Initial safety results from CompLEEment-1, from the first 56 days of follow-up, demonstrate the tolerability of RIBO+LET in older patients, consistent with the overall patient population. NCT02941926.
Citation Format: Ring A, Borstnar S, Ferreira A, Azim HA, Cottu P, Lu J, Martin M, Zamagni C, Beck JT, Zhou K, Wu J, Menon L, De Laurentiis M. Ribociclib (RIBO) + letrozole (LET) in older patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Preliminary subgroup results from the phase 3b CompLEEment-1 trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-16.
Collapse
|
150
|
Polley MYC, Dickler MN, Johnston S, Goetz MP, de la Haba J, Loibl S, Mehta RS, Bergh J, Roberston J, Barlow W, Liu H, Tenner K, Martin M. Abstract P2-07-05: A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced stage breast cancer treated with first-line endocrine therapy. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-07-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Endocrine based therapy is an effective strategy to manage hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). However, nearly all patients exhibit/develop either de novo or acquired resistance. While prognostic biomarkers of endocrine responsiveness are well established for the adjuvant treatment in ER+ breast cancer, less is known regarding prognostic and predictive biomarkers of response in the first line ABC setting. We sought to develop a clinical calculator based on clinical criteria for predicting progression-free survival (PFS) and overall survival (OS) of women with HR+/HER2- ABC who will be receiving endocrine monotherapy as first-line treatment for ABC.
Methods: The development of the clinical calculator will be based on data from modern clinical trials in women with HR+/HER2- ABC. The studies to be included in the final analyses are given in Table 1. The control arm data from trials1-6 will form the training dataset (N = 1,223) and be used to construct the clinical prediction models. Variables considered include age, race, ECOG status, disease measurability, body mass index, disease-free interval, number of metastatic sites, locations of metastatic sites, prior endocrine therapy, and prior chemotherapy. Missing values will be imputed using single imputation with all variables included in the imputation model. For continuous variables, restricted cubic splines will be used to determine if non-linear effects may be more appropriate. The Lasso regression will be used as a variable selection technique to reduce the dimensionality of covariates; initially all pairwise interactions will be included in the model. Following Lasso regression, the multivariable Cox proportional hazards models will be constructed for PFS and OS including only variables retained in Lasso. The final model will be internally validated for discrimination and calibration using 10-fold cross-validation. External validation will be performed using control arm data from EGF 30008 (N = 536).
Results: To date, control arm data from four trials (trials 1-4) have been received. The preliminary results presented here are based on pooled data from C40503 and LEA, for which data elements have been harmonized. Models for predicting PFS and OS have good calibration and are associated with bias-corrected C-indices of 0.61 and 0.65, respectively. These models will be updated using pooled data from trials 1-6.
Conclusions: Our preliminary data demonstrate that clinical calculators based on baseline clinical factors can provide accurate prediction of PFS and OS in patients with HR+/HER2- ABC treated with first-line ET. If validated, these tools may be used for risk stratification in future clinical trials and to identify patients who may require more or less aggressive therapy.
Table 1:Studies to be includedTrial NumberTrial NameTrial PISample Size in Control Arm1C40503Maura Dickler152 (letrozole)2LEAMiguel Martin179 (letrozole)3FACTJonas Bergh188 (anastrozole)4FALCONJohn Robertson194 (anastrozole)5S0226Rita Mehta345 (anastrozole)6MONARCH 3Matthew Goetz165 (nonsteroidal AI)7EGF 30008Stephen Johnston536 (letrozole)
Citation Format: Polley M-YC, Dickler MN, Johnston S, Goetz MP, de la Haba J, Loibl S, Mehta RS, Bergh J, Roberston J, Barlow W, Liu H, Tenner K, Martin M. A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced stage breast cancer treated with first-line endocrine therapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-07-05.
Collapse
|